Lupus & antiphospholipid syndrome
Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A “post-hoc” analysis of participants in the BLISS-LN and open label extension study belonging to a single center
Authors' conclusion
Although the number of patients is insufficient to be able to draw unquestionable conclusions, adding Belimumab to the standard of care treatment with MMF would seem to increase the possibility of achieving a CCR, CHR, and a lower rate of relapses during treatment and long follow-up.
Study context
- Population
- LN patients who participated in the BLISS LN trial at a single centre (OMI) in Argentina; MMF continued until a second biopsy
- Participants
- 20 patients
- Comparison
- MMF + Belimumab vs MMF + Placebo
- Belimumabn = 10
- Placebon = 10reference
Methodological detailssingle-centre
- Single-centre
Primary result
As reported in the abstract
Complete clinical response (CCR)
Placebo
7
events
Further findings
Events
| Outcome | Belimumab | Placebo |
|---|---|---|
| Complete histological response (CHR) | 9 | 5 |
| Flares | 0 | 2 |
Original publication
Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A “post-hoc” analysis of participants in the BLISS-LN and open label extension study belonging to a single center. Lupus. Published 27 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →